Insights from BCC Research

Blood Industry Gets a Transfusion from an Aging Population

Posted by Laurie L. Sullivan on Jun 5, 2017 11:00:00 AM

1PHM1199B-blood.jpgEnsuring safety of the blood supply, the demand for plasma-derived therapeutics, and an aging population are factors driving growth in the global blood industry. The annual growth of plasma-derived therapies, used mostly to treat rare disorders, may exceed 10%. Hemophilia, hepatitis, cancer, and kidney failure are among the many conditions that are managed by blood transfusion or by therapy with plasma or plasma-derived products. An aging population suggests that there will be many more patients who need such products in the future. At a compound annual growth rate (CAGR) of 4.9%, BCC Research predicts the value of the global blood industry to increase from $33.5 billion in 2016 to $42.6 billion in 2021.

Read More

Topics: Life Sciences, Healthcare

Latest Advances in Bionics: Hands That Can See, Robots That Can Feel

Posted by Laurie L. Sullivan on May 25, 2017 10:00:00 AM

BCC Research recently analyzed the global market for bionic devices, assessing the latest sensor and material technologies that are being used in advanced bionic ears, eyes, hearts, limbs, and exoskeletons. These bionic components are driving market growth and changing the lives of millions of people.

Read More

Topics: Life Sciences, Healthcare

Is There a Silver Lining for the Medical Device Coatings Market?

Posted by Laurie L. Sullivan on May 9, 2017 7:47:42 PM

Medical device coatings are essential to healthcare. Up to 80% of medical devices require at least one type of coating material or surface treatment. Coatings that enhance biocompatibility have improved the quality of implanted electronic devices and artificial joints. Catheters and examining room surfaces with antimicrobial coatings have become frontline defenses against antibiotic-resistant infections such as MRSA.

Read More

Topics: Life Sciences, Healthcare

Liquid Biopsies Still Sizzling As Market Heats Up

Posted by Laurie L. Sullivan on Feb 6, 2017 11:30:00 AM

A year ago, we reported that the liquid biopsy market got off to big start in 2016. Now, the field is hotter than ever, with new investments, partnerships, and initiatives toward making liquid biopsies a standard of care. Liquid biopsies have been likened to a Holy Grail of cancer treatment. By means of a simple blood draw, liquid biopsies aim to replace needle biopsies of solid tumors, which can be expensive for the healthcare system as well as painful for patients. For diagnosis of cancer, liquid biopsies could spare some of the risky tissue biopsies and reduce reliance on computed tomography scans, which must be limited because of the danger posed by overexposure to radiation.

Read More

Topics: Healthcare, Biotechnology